Vasoreactivity in Carriers of Genetic Polymorphisms

Phase 1 Unknown 100 enrolled Heidelberg University

Non-randomizedSingle-groupDouble-blindEct

Summary

The objective of the study is to assess the impact of genetic variation (especially polymorphisms of the gene coding endothelial nitric oxide synthase (eNOS) and the bradykinin B2 receptor gene) on venous and arterial responsiveness to vasodilators in healthy individuals without cardiovascular risk factors.

Timeline

Start: 1999-11
Primary completion: —
Completion: 2006-12

Publications

Background Fricker R, Hesse C, Weiss J, Tayrouz Y, Hoffmann MM, Unnebrink K, Mansmann U, Haefeli WE. Endothelial venodilator response in carriers of genetic polymorphisms involved in NO synthesis and degradation. Br J Clin Pharmacol. 2004 Aug;58(2):169-77. doi: 10.1111/j.1365-2125.2004.02130.x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Acetylcholine	Small molecule	—	—
Subject	Bradykinin	Protein / enzyme biologic	—	—
Subject	Sodium Nitroprusside	Unknown	—	—

Indications

No indication recorded.